Entering text into the input field will update the search result below

Vertex Approaches Its Indicated BuyAt Price

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Nothing is within one percent of the Algo-indicated BuyAt or SellAt prices. Two stocks, BIO and GSHD, were very briefly below their indicated BuyAt but have rebounded a little. As the Algo has adjusted to today’s volatility, both BuyAt prices have fallen.

With today’s volatility the indicated sell at price of GMAB has declined to $41.60. It was $43.31 a couple of days ago. Current market $40.52.

Today’s Graphs – VRTX Summary Report and Algo-Indicated BuyAt and SellAt prices

VRTX seems to have fallen into some disfavor. It is now trading at 4% above its indicated BuyAt price of $217.72. The issues are described in this Seeking Alpha article:

Vertex Pharmaceuticals: A Play On Market Overreaction

As indicated below, profitability, financial strength trends remain highly favorable. (Click on to access Detailed Report).

No alt text provided for this imageThe chart below indicates BuyAt and SellAt levels as determined by the Algo. Essentially, it shows the backtest results to put the attractiveness of the current price in perspective. (Click on to enlarge).

No alt text provided for this image

Purchases and sales made at the Algo-indicated prices would have generated a return of just under 30% per transaction, average holding time of 1.2 months, return annualized of 287%.

Risk Research Inc. provides research tools to professional growth investors based on proprietary AI software.

Analyst's Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in VRTX over the next 72 hours.

We offer this research as insight into what we do in our own portfolio rather than as a recommendation or offer to buy or sell securities. This research should not be your sole source of information. It is based on probabilities, not certainties.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.